Literature DB >> 31412356

Use of Intrauterine Devices and Risk of Human Immunodeficiency Virus Acquisition Among Insured Women in the United States.

Julia L Marcus1, Jonathan M Snowden2, Mara E Murray Horwitz1, Sengwee Toh1, Casie Horgan1, Rong Chen Tilney1, Rajani Rajbhandari1, Soowoo Back1, Daniel J Westreich3.   

Abstract

Concerns have been raised about progestin-containing contraceptives and the risk of human immunodeficiency virus (HIV) acquisition. Based on health insurance data from women in the United States with intrauterine device (IUD) insertions during 2011-2018, there was no increased risk of incident HIV diagnosis for levonorgestrel-releasing IUDs versus copper IUDs.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  copper intrauterine devices; hormone releasing intrauterine devices; human immunodeficiency virus; intrauterine devices; long-acting reversible contraception

Year:  2020        PMID： 31412356      PMCID： PMC7201418          DOI： 10.1093/cid/ciz791

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  10 in total

1.  Characteristics of users of intrauterine devices and other reversible contraceptive methods in the United States.

Authors:  Xin Xu; Maurizio Macaluso; Jennifer Frost; John E Anderson; Kathryn Curtis; Scott D Grosse
Journal:  Fertil Steril       Date:  2011-09-13       Impact factor: 7.329

2.  Lifetime risk of a diagnosis of HIV infection in the United States.

Authors:  Kristen L Hess; Xiaohong Hu; Amy Lansky; Jonathan Mermin; Hildegard Irene Hall
Journal:  Ann Epidemiol       Date:  2017-02-21       Impact factor: 3.797

3.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.

Authors:  Lauren J Ralph; Sandra I McCoy; Karen Shiu; Nancy S Padian
Journal:  Lancet Infect Dis       Date:  2015-01-09       Impact factor: 25.071

4.  Levonorgestrel in contraceptives and multipurpose prevention technologies: does this progestin increase HIV risk or interact with antiretrovirals?

Authors:  Chelsea B Polis; Sharon J Phillips; Sharon L Hillier; Sharon L Achilles
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

5.  Unmeasured confounding and hazard scales: sensitivity analysis for total, direct, and indirect effects.

Authors:  Tyler J VanderWeele
Journal:  Eur J Epidemiol       Date:  2013-02-01       Impact factor: 8.082

Review 6.  Assessing the effect of hormonal contraception on HIV acquisition in observational data: challenges and recommended analytic approaches.

Authors:  Chelsea B Polis; Daniel Westreich; Jennifer E Balkus; Renee Heffron
Journal:  AIDS       Date:  2013-10       Impact factor: 4.177

7.  Changes in genital tract immune cell populations after initiation of intrauterine contraception.

Authors:  Sharon L Achilles; Mitchell D Creinin; Kevin A Stoner; Beatrice A Chen; Leslie Meyn; Sharon L Hillier
Journal:  Am J Obstet Gynecol       Date:  2014-05-13       Impact factor: 8.661

8.  Effects of the levonorgestrel-releasing intrauterine device on the immune microenvironment of the human cervix and endometrium.

Authors:  Uma Shanmugasundaram; Joan F Hilton; J William Critchfield; Ruth M Greenblatt; Linda C Giudice; Sarah Averbach; Dominika Seidman; Barbara L Shacklett; Karen Smith-McCune
Journal:  Am J Reprod Immunol       Date:  2016-08       Impact factor: 3.886

9.  HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial.

Authors: 
Journal:  Lancet       Date:  2019-06-13       Impact factor: 79.321

Review 10.  An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women.

Authors:  Chelsea B Polis; Kathryn M Curtis; Philip C Hannaford; Sharon J Phillips; Tsungai Chipato; James N Kiarie; Daniel J Westreich; Petrus S Steyn
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.